a specific activity in the murine thymocyte proliferation assay equivalent to that of the 115-270 parent protein and exhibited significant biological activity in stimulating the production of collagenase and prostaglandin E2 by synovial cells and fibroblasts. The more extensive amino-terminal deletion analog rIL-1 (144-270) was inactive in all biological assays and failed to compete in the receptor binding assay. The carboxylterminal deletion analog rIL-1 (131-257, 270) competed less efficiently (by a factor of 100) in the receptor binding assay, retained weak biological activity on synovial cells and fibroblasts, and only demonstrated full intrinsic activity in the thymocyte proliferation assay when 100-200 times more protein was assayed. These results suggest that biologically active murine IL-1 polypeptides are at least 127 amino acids long and are derived from the carboxyl terminus of the 270-amino acid precursor. Furthermore, it appears that the integrity of the carboxyl terminus ofthe 270-amino acid precursor is important for activity but that different amino termini can be utilized to generate molecules with equivalent specific activities. This amino-terminal end flexibility supports a processing model for IL-1 maturation that partially explains IL-1 polypeptide heterogeneity.
Interleukin 1 (IL-1) is a macrophage-derived polypeptide hormone that modulates immune and inflammatory responses (1, 2). Biochemical studies (3, 4) have revealed that IL-1 secreted by the murine macrophage-like tumor cell line P388D1 exhibits size (Mr 12,000-19,000) and charge microheterogeneity (pI 4.6-5.2). Pulse-labeling experiments, as well as cell-free translation experiments using mRNA from stimulated cells, have indicated that IL-1 is initially synthesized as a Mr 33,000 polypeptide that is the precursor of the heterogeneous collection of low molecular weight IL-1 polypeptides found in the culture fluid of stimulated cells (5) . The cDNA encoding the Mr 33,000 murine IL-1 precursor has been cloned and expressed in Escherichia coli (6) . This IL-1 cDNA codes for a polypeptide of 270 amino acids with a calculated Mr of 31,026. Sequencing of P388D1-derived IL-1 has revealed that a subset of molecules possesses an amino terminus that begins at position 115 of the 270-amino acid precursor, leading to the prediction that IL-1 bioactivity maps to the carboxyl-terminal half of the precursor. To confirm this, the carboxyl-terminal 156 amino acids (i.e., amino acids 115-270) of the precursor were expressed in E. coli, yielding a protein that reacts with highly specific goat anti-IL-i antibodies (4) . The recombinant protein is active in the murine thymocyte proliferation assay with a specific activity identical to that of purified P388D,-derived IL-1.
Mouse recombinant IL-1 (rIL-1) is also active in a number of other assays (7) , proving that many of the activities previously ascribed to IL-1 are exhibited by a single molecule.
Gene cloning experiments have proven that a human IL-1 gene family exists. Human IL-1 cDNA clones encoding proteins of269 (IL-1,i) and 271 amino acids (IL-la) have been isolated (7) (8) (9) . Murine and human IL-la precursors are -60%o homologous in amino acid sequence but only =25% homologous with human IL-1i8. Amino-terminal sequence analyses of the human IL-1,i protein showed some heterogeneity (9, 10) , but the major sequence matched the predicted sequence of Auron et al. (8) beginning at amino acid position 117. This protein sequence information, together with the homology between murine and human IL-la, prompted E. coli expression experiments that demonstrated that fragments 150-160 amino acids long from the carboxyl terminus of the human IL-la and IL-1,8 precursors contained IL-1 bioactivity (7, 9 Fig. 1 ). Deletions were created by oligonucleotidedirected mutagenesis on nicked heteroduplex plasmid DNA (11) or by removal of restriction fragments. E. coli strain MC1061 (12) containing the plasmid pRK248cIts (13) was used for transformation (14) and production of recombinant proteins (15) . Homogeneous murine rIL-1 proteins were obtained by using a two-step purification procedure (7) involving isolation of inclusion bodies (16) from an E. coli cell lysate, followed by size-exclusion chromatography on Sephacryl S-200 equilibrated with 5 M guanidine HCl. The purity of rIL-1 proteins was assessed by NaDodSO4/polyacrylamide gel electrophoresis (17) and amino-terminal end sequence analysis.
Biological activity ofthe rIL-1 analogs was evaluated in the standard murine thymocyte proliferation assay (4) . Human rheumatoid synovial cells (18) and human dermal fibroblasts (CRL 1445, American Type Culture Collection) (19) were used to measure IL-i-induced prostaglandin E2 (PGE2) and collagenase production. Competitive IL-1 receptor binding to EL-4 thymoma cells was measured as described (20 Fig. 2A, lane 4) .
Oligonucleotide-directed mutagenesis was used to generate plasmid pEV-vrf2/IL-1 (144-270) (Fig. 1C) . This plasmid encodes the rIL-1 (144-270) analog (Fig. 1B) in which an additional 13 amino acids (Fig. UA, box b) were deleted from the amino terminus. The accumulation of rIL-1 (144-270) in E. coli was about equal to that of rIL-1 (131-270) (Fig. 2A,  compare lanes 2 and 3) .
To assess the biological activity of these analogs in the different cell assays and to examine their ability to bind to the IL-1 receptor, rIL-1 (131-270), rIL-1 (131-257, 270), and rIL-1 (144-270) were purified to homogeneity. The analog proteins appeared to be >95% pure as determined by NaDodSO4/polyacrylamide gel electrophoresis (Fig. 2B) and by amino-terminal sequence analysis. A comparison of their electrophoretic mobilities demonstrated that the molecular weights of these proteins were identical in total cell extracts ( Fig. 2A ) and after purification (Fig. 2B) .
Murine Thymocyte Proliferation. The activities of the purified rIL-1 proteins were determined in the thymocyte proliferation assay (Table 1 ). The amino-terminal deletion analog rIL-1 (131-270) exhibited a specific activity equivalent to the rIL-1 (115-270) parent protein and purified P388D1-derived IL-1 (6) . These results indicate that the first 16 amino acids at the amino terminus of rIL-1 (115-270) do not play an important role in the structural integrity and resultant biological activity of this molecule. We elected not to purify rIL-1 (115-270) for subsequent biological experiments because rIL-1 (131-270) was produced at a much higher level in E. coli and was more easily purified. The more extensive amino-terminal deletion analog rIL-1 (144-270) had no detectable activity in the thymocyte proliferation assay. We estimate this analog is at least 3 orders of magnitude less active than the parental molecules, given the detection limits of this assay. The carboxyl-terminal deletion analog rIL-1 (131-257, 270) was capable of stimulating maximal thymocyte proliferation but only at concentrations 100-to 200-fold higher than its parental molecules; hence, in this comparison, this analog possesses <1% activity.
Production of Collagenase and PGE2 by Human Rheumatoid Synovial Cells and Dermal Fibroblasts. Human rheumatoid synovial cells were maintained in culture until their ability to spontaneously produce collagenase (procollagenase) and PGE2 was greatly diminished (=3 weeks). Unstimulated human dermal fibroblasts (CRL 1445) produced very low levels of PGE2 (0.5 pmol/ml) and no detectable collagenase activity. The synovial cells and dermal fibroblasts were stimulated with various concentrations of purified rIL-1 analogs. As shown in Fig. 3, rIL-1 (131-270) induced the CRL 1445 cells to produce substantial levels of collagenase (Fig.  3A) and PGE2 (Fig. 3B) . The collagenase response was more sensitive to IL-1 stimulation since the quantity of rIL-1 (131-270) necessary to stimulate the half-maximal production of PGE2 (--35 ng/ml) was about seven times greater than that necessary to stimulate the half-maximal collagenase level (U5 ng/ml). The more extensive amino-terminal deletion analog rIL-1 (144-270) was completely inactive on CRL 1445 cells in both of these assays. The carboxyl-terminal deletion analog rIL-1 (131-257, 270) did not stimulate CRL 1445 cells to produce PGE2 (Fig. 3B ) but did induce a minimal collagenase response relative to that achieved by rIL-1 (131-270) stimulation (Fig. 3A) . In the synovial cell assay, the pattern of the results was very similar to that observed for the dermal fibroblasts. The half-maximal level of collagenase produced (Fig. 3A) was achieved with only 5 ng of rIL-l (131-270) per ml, whereas the half-maximal PGE2 response (Fig. 3B) (Fig. 4) , with half-maximal inhibition observed at 20 ng/ml. The doseresponse for the carboxyl-termiinal deletion analog rIL-1 (131-257, 270) was markedly shifted to the right with >1000 ng/ml required to inhibit binding by 50%. The more extensive deletion analog rIL-1 (144-270) failed to inhibit binding at all tested concentrations. analog, rIL-1 (131-257, 270), that competes in the receptor binding assay and is biologically active only at concentrations 100-fold greater than its undeleted parent. For the different IL-1 protein analogs there is good correlation between activity in the murine thymocyte proliferation assay, activity on human synovial cells and dermal fibroblasts, and ability to compete in the receptor binding assay. We have not attempted to create more extensive carboxyl-terminal deletions to identify completely inactive molecules.
Several conclusions can be drawn from these results.
(ffIt appears that IL-1 polypeptides must be >127 amino acids long to exhibit efficient biological activity. Polypeptides <127 amino acids long that retain IL-1 bioactivity have greatly reduced specific activities. Recently, using sitedirected mutagenesis, we have generated single amino acid substitutions throughout the 127-amino acid core that result in biologically inactive proteins (T.D., unpublished), further confirming that this entire structure is necessary for activity. Although we favor the interpretation that biologically active IL-1 polypeptides must be at least 127 amino acids long, it is conceivable that a smaller active fragment exists but that for certain deletion and point mutation analogs the conformation around the active region has been altered rendering these larger molecules inactive. There are reports of a 4.2-kDa peptide with IL-1 activity identified in plasma from febrile patients (21); however, the precise structure and specific activity of this peptide remain to be determined.
(
ii) It appears that the integrity of the 270-amino acid precursor's carboxyl terminus is important for biological activity but that different amino termini can be utilized to generate molecules with equivalent specific activities. These findings support a processing model that predicts that biologically active murine IL-1 is derived from the carboxylterminal half of the 270-amino acid precursor form through amino-terminal processing events (6) . The predicted aminoterminal end heterogeneity of IL-1 can also be inferred from the results of sequencing studies with murine (6) and human IL-1 (9, 10). Since processed IL-1 polypeptides are not observed inside the macrophage (5), IL-1 precursor processing may occur extracellularly or at the cell membrane. The mechanism by which the IL-1 precursor is secreted, the nature of the processing enzymes, and the fate of the amino-terminal portion of the precursor are all unanswered questions. It is curious that the amino terminus of the precursor forms of human IL-la and murine IL-1 is well conserved but not necessary for biological activity; it is possible that the IL-1 precursor, or this amino-terminal portion, has another function. We have noticed that the murine IL-1 precursor synthesized in E. coli is biologically active (C. P. Hellmann and P.T.L., unpublished), as is the human IL-la precursor synthesized in rabbit reticulocyte lysates (9) . However, it is not clear ifthese precursor proteins are intrinsically active or whether local proteolysis in the thymocyte assay creates active IL-1 fragments.
(iii) Since there is good correlation between activities in the different cell bioassays for the different murine IL-1 analogs, it appears that IL-1 cell-surface receptors on different cells recognize the same structural determinants on the IL-1 molecule. This is also supported by the interaction of the various analogs in an IL-1 receptor assay. We have recently characterized the binding of radiolabeled murine IL-1 (131-270) to murine EL-4 thymoma cells (20) . The 125I-IL-1 binds to these cells in a specific and saturable manner and with high affinity. In this competitive binding assay, the murine IL-1 analogs demonstrate different receptor affinities, which correlate well with activities on T cells and fibroblasts. However, it remains to be directly determined if IL-1 receptors on different cells are identical.
Since human IL-la is the homolog (7, 9) of the munine gene product examined in this study, it is likely that our conclusions apply to this human protein as well. Indeed, preliminary deletion analysis of recombinant human IL-la supports our murine findings (T.D., unpublished). To date it has not been determined if IL-la and IL-1/3 have an identical spectrum of biological activities; however, it appears that these two proteins interact with the same cell-surface receptor on T cells (20) . In spite of the modest sequence homology between IL-la and IL-il, the overall comparability of these molecules offers the likelihood that structure-function studies on these two macrophage proteins will reveal significant similarities.
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